Jacques-Pierre Fontaine, MD
Articles by Jacques-Pierre Fontaine, MD

Ensuring Comprehensive Support and Long Term Success for Patients Receiving DFLOT
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Discover how specialized cancer care, including nurse navigators and telehealth, enhances patient outcomes and quality of life post-treatment.

Managing Toxicity, Monitoring Needs, and Logistical Realities of DFLOT in Perioperative Care
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the management of immune-mediated side effects in perioperative cancer treatment, emphasizing patient care and monitoring strategies.

Applying DFLOT to a Real World Case of Resectable Stage III GE Junction Cancer
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Explore the complexities of managing a Stage 3 gastric adenocarcinoma case, focusing on surgical options and perioperative treatment strategies.

Strengths, Limitations, and Real World Adoption of the MATTERHORN DFLOT Strategy
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the strengths and limitations of the Matterhorn study, highlighting advancements in immunotherapy for upper GI cancer and future research directions.

Counseling Patients on PCR, Residual Disease, and the Role of Adjuvant Therapy After DFLOT
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Oncologists discuss the significance of PCR and MPR rates in patient counseling, emphasizing treatment benefits and survival outcomes.

Integrating PD-L1 Testing and Practical Implications for DFLOT Adoption
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the importance of PD-L1 testing in treatment decisions for gastric cancer, emphasizing personalized approaches and improved patient outcomes.

Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing patient quality of life and treatment decisions.

Interpreting Endpoints and Pathologic Response: Applying EFS, PCR, and Biomarkers in Perioperative Decision Making
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing the importance of patient quality of life.

DFLOT Implementation: Surgical Timing, Patient Selection, and the Evolving Role of Adjuvant Immunotherapy
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Doctor Fontaine discusses the importance of patient selection for preoperative chemotherapy and the effectiveness of immune checkpoint inhibitors in surgery outcomes.

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Managing FLOT Tolerability, Assessing Pathologic Response, and Addressing Unmet Needs in the Perioperative Setting
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Evaluating Total Neoadjuvant Approaches: Balancing Treatment Intensity, Surgical Timing, and Patient Selection
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss tailored approaches to neoadjuvant therapy for esophageal and gastroesophageal junction cancers, emphasizing multidisciplinary care and surgical precision.

Selecting Neoadjuvant Strategies for Esophageal and GEJ Adenocarcinoma Across Multidisciplinary Practices
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.

Current Standards in Resectable Gastric and GEJ Adenocarcinoma: Multidisciplinary Perspectives on Perioperative Management
ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.